What are the proven medical interventions to decrease the risk of AMD progression?

The use of AREDS2 supplements has been scientifically validated as an effective intervention to decrease the risk of progression in age-related macular degeneration (AMD). The Age-Related Eye Disease Study 2 (AREDS2) trial specifically demonstrated that a formulation containing antioxidants and zinc could reduce the risk of advanced AMD in individuals with intermediate AMD or those with late AMD in one eye. This particular formulation included lutein and zeaxanthin in place of beta-carotene, addressing potential health issues linked to beta-carotene in certain populations, such as smokers.

Incorporating these supplements as part of a patient's management plan has become a widely accepted practice for individuals at risk, as they have shown potential in slowing down the progression to more severe forms of the disease. The evidence supporting AREDS2 has made it a cornerstone in the preventive strategy for AMD, highlighting the importance of the specific nutrients included and the rigor of the clinical trial backing their efficacy.